Strategies to reduce perioperative morbidity in cytoreductive surgery

Hepato-Gastroenterology

Volumn 55, Issue 86-87, 2008, Pages 1523-1529

  Müller, Herwart ^a   Hahn, Michael ^a   Weller, Lutz ^a   Simsa, Jaromir ^b  

^a Department of Surgical Oncology   (Germany)

^b Hospital Kolin   (Czech Republic)

Author keywords

Complications; Cytoreduction; Hyperthermia; Inflammatory response; Intraperitoneal chemotherapy; Peritoneal carcinomatosis

Indexed keywords

CYTOSTATIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HOSPITALIZATION; HUMAN; INFLAMMATION; INTRAPERITONEAL HYPERTHERMIC CHEMOPERFUSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERIOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK REDUCTION; SEX RATIO; SURGICAL RISK;

ADENOSINE; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLOOD LOSS, SURGICAL; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; PERITONEAL NEOPLASMS; PERITONEUM; RECEPTORS, ADENOSINE A2;

EID: 57049160437     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Sugarbaker PH: Peritonectomy procedures. Ann Surg 1995; 221:29-42.
2. Elias D, Ouellet JF: Intraperitoneal chemohyperthermia. Rationale, technique, indications and results. Surg Oncol Clin North Am 2001; 10:915-933.
3. Witkamp AJ, de Bree E, Kaag MM, van Slooten GW, van Coevorden F, Zoetmulder FAN: Extensive surgical cytoreduction and intraoperative hyperthermic intrapertoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg 2001; 88:458-463.
4. Sugarbaker PH: New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritomei syndrome? Lancet 2006; 69-76.
5. Sugarbaker PH, Chang D: Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999; 6:727-731.
6. De Simone M, Scuderi S, Vaira M: Treatment of pseudomyxoma peritonei with two times - cytoreduction and hypertermic antiblastic peritoneal perfusion (HAPP). J Experi Clinical Cancer Res 2003; 22(4):25-28.
7. Glehen O, Mohamed F, Sugarbaker PH: Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 2004; 240(2):278-285.
8. Witkamp AJ, de Bree E, Kaag MM, et al: Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 2001; 37:979-984.
9. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR: Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 2000; 66:561-568.
10. Elias D, Blot F, El Otmany A, et al: Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001; 92:71-76.
11. Verwaal VJ, van Ruth S, de Bree E: A randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. JCO 2003; 21(20):3737-3743.
12. Yan TD, Esquivel J, Carmignani P, Sugarbaker PH: Cytoreduction and intraperitoneal chemotherapy for the management of non-gynecological peritoneal surface malignancy. J Exper Clin Cancer Res 2003; 22(4):109-117.
13. Gadducci A, Iacconi P, Fanucchi A, Cosio S, Teti G, Genazzani AR: Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer Anticancer Res 2000; 20(3B):1959-1964.
14. Raspagliesi F, Kusamura S, Campos Torres JC: Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. Eur J Surg Oncol 2006; 32(6):671-675.
15. Chi DS, McCauthy K, Diaz JP, et al: Guidelines and selection criteria for secondary cytoredetive surgery in patients with recurrent, platinum sensitive epithelial ovarian carcinoma. Cancer 2006; 106:1933-1939.
16. Yu W, Whang I, Chuang HY, Averbach A, Sugarbaker PH: Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg 2001; 25:985-990.
17. Yonemura Y, Fujimura T, Nishimura G, et al: Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 1996; 119:437-444.
18. Sugarbaker PH, Yan TD, Stuart OA, Yoo D: Comprehensive management of diffuse malignant peritoneal mesothelioma Eur J Surg Oncol 2006; 32:686-691.
19. Esquivel J, Vidal-Jove J, Steves MA, Sugarbaker PH: Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery 1993; 113:631-636.
20. Butterworth SA, Panton ONM, Klaassen DJ, Shah AM, McCregor GI: Morbidity and mortality associated with intraperitoneal chemotherapy for pseudomyxoma peritonei. Am J Surg 2002; 183:529-532.
21. Stephens AD, Alderman R, Chang D, Edwards GD, Esquivel J, Sebbag G, Steves MA, Sugarbaker PH: Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the open technique. Ann Surg Oncol 1999; 6:790-796.
22. Nathan C: Points of control in inflammation. Nature 2002; 420:846-852.
23. Chavarria A, Alcocer-Varela J: Is damage in central nervous system due to inflammation? Autoimmun Rev 2004; 3:251-260.
24. Donnahoo KK, Meng Y, Ayala A, et al: Early kidney TNF-expression mediates neutrophil infiltration and injury after renal ischemia-reperfusion. Am J Physiol 1999; 277:922-929.
25. Mokart D, Capo C, Blache JL, et al: Early postoperative compensatory anti-inflammatory response syndrome is associated with septic complications after major surgical trauma in patients with cancer. Br J Surg 2002; 89(11):1450-1456.
26. Feldman L, Barkun J, Barkun A et al: Measuring post-operative complications in general surgery patients using an outcome-based strategy: comparison with complications presented at morbidity and mortality rounds. Surgery 1997; 122:711-720.
27. Kurz A, Sessler DI, Lenhardt R: Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. Study of Wound Infection and Temperature Group. N Engl J Med 1996; 334:1209-1215.
28. Flores-Maldonado A, Medina-Escobedo CE, Rios-Rodriguez HM, Fernandez-Dominguez R: Mild perioperative hypothermia and the risk of wound infection. Arch Med Res 2001; 32(3):227-231.
29. Frank SM, Fleisher LA, Breslow MJ, Higgins MS, Olson KF, Kelly S, Beattie C: perioperative maintenance of normothermia reduces the incidence of morbid cardiac events. A randomized clinical trial. JAMA 1997; 277(14):1127-1134.
30. Melling AC, Ali B, Scott EM, Leaper DJ: Effects of pre-operative warming on the incidence of wound infection after clean surgery: a randomised controlled trial. Lancet 2001; 358(9285):876-880.
31. Lobo D, Bostock KA, Neal KR, et al: Effect of salt and water balance on recovery of gastrointestinal function after elective colonic resection: a randomized controlled trial Lancet. 2002; 359:1812-1818.
32. Lang K, Boldt J, Suttner S, et al: Colloides versus crystalloids and tissue oxygen tension in patients undergoing major abdominal surgery. Anesth Analg 2001; 93:405-409.
33. Moller AM, Pedersen T, Svendsen P-E, et al: Perioperative risk factors in elective pneumonectomy: the impact of excess fluid balance. Eur J Anaesthesiol 2002; 19:57-62.
34. Lowell JX Schifferdecker C, Driscoll DF, et al: Post-operative fluid overload: not a benign problem. Crit Care Med 1990; 18:728-733.
35. Brandstrup B, Tonnesen H, Beier- Holgerson R, et al: Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens. Ann Surg 2003; 238(5):641-648.
36. van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345:1359-1367.
37. Coursin DB, Connery LE, Ketzler JT: Perioperative diabetic and hyperglycemic management issues. Crit Care Med. 2004; 32:116-125
38. Belda FJ, Aguilera L, Garcia de la Asuncion J, et al: Supplemental perioperative oxygen and the risk of surgical wound infection: a randomized controlled trial. JAMA 2005; 294(16):2035-2042.
39. Greif R, Akza O, Horn EP, et al: Supplemental perioperative oxygen to reduce the incidence of surgical wound infection NEJM 2000; 342:161-167.
40. Royston D, Bistrup BP, Taylor KM, Sapsford RN: Effects of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987; 2:1289-1291.
41. Alajmo F, Calamai G, Perna AM, et al: High-dose aprotinin: Hemostatic effects in open heart operations. Ann Thorac Surg 1989; 48:536-539.
42. Fraedrich G, Weber C, Bernard C, Hettwer A, Schlosser V: Reduction of blood transfusion requirement in open heart surgery by administration of high doses of aprotinin - Preliminary results. Thorac Cardiovasc Surg 1989; 37:89-91.
43. Godet G, Bertrand M, Samama CM, et al: Aprotinin to decrease bleeding and intraoperative blood transfusion requirements during descending thoracic and thoracoabdominal aortic aneurysmectomy using cardiopulmonary bypass. Ann Vasc Surg 1994; 8:452-456.
44. Porte RJ, Molenaar IQ, Begliomini B, et al: Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. Lancet 2000; 355:1303-1309.
45. Samama CM, Dietrich W, Horrow J, et al: Structure, pharmacology, and clinical use of antifibrinolytic agents. In: Bachman F (Ed.). Handbook of experimental pharmacology, fibrinolytics and antifibrinolyties. Heidelberg: Springer, 2000; pp. 559-585.
46. Cronstein BN: Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994; 76:5-13.
47. Karmazyn M, Cook MA: Adenosine A1 receptor activation attenuates cardiac injury produced by hydrogen peroxide. Circ Res 1992; 71:1101-1110.
48. Heurteaux C, Lauritzen I, Widmann C, Lazdunski M: Essential role of adenosine, adenosine A1 receptors, and ATP-sensitive K-channels in cerebral ischemic preconditioning. Proc Natl Acad Sci USA 1995; 92:4666-4670.
49. Yao K, Kusaka H, Sato K, Karasawa A: Protective effects of KW-3902, a novel adenosine A1-receptor antagonist, against gentamicin-induced acute renal failure in rats. Jpn J Pharmacol 1994; 65:167-170.
50. Donnahoo KK, Shames BD, Harken AH, Meldrum DR: The role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol 1999; 162:196-203.
51. Lappas CM, Rieger JM, Linden J: A2A adenosine receptor induction inhibits IFN- production in murine CD4+ T cells. J Immunol 2005; 174:1073-1080.
52. Fredhohn BB, Zhang Y, van der Ploeg I: Adenosine A2A receptors mediate the inhibitory effect of adenosine on formyl-Met-Leu-Phe-stimulated respiratory burst in neutrophil leucocytes. Naunyn-Schmiedeberg's Arch Pharmacol 1996; 354:262-267.
53. Daemen MA, van't Veer C, Denecker G, et al: Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemostasis 1996; 75(2):224-228.
54. Bullough, DA, Magill MJ, Firestein GS, Mullane KM: Adenosine activates A2 receptors to inhibit neutrophil adhesion and injury to isolated cardiac myocytes. J Immunol 1995; 155:2579-2596.
55. Bouma MG, Van Den Wildenberg FA, Buurman WA: Adenosine inhibits cytokine release and expression of adbesion molecules by activated human endothelial cells. Am J Physiol 1996; 270:522-529.